Risk perception in natalizumab-treated multiple sclerosis patients and their neurologists.

@article{Heesen2010RiskPI,
  title={Risk perception in natalizumab-treated multiple sclerosis patients and their neurologists.},
  author={Christoph Heesen and Ingo Kleiter and Franziska Nguyen and Nina Sch{\"a}ffler and J{\"u}rgen Kasper and Sascha K{\"o}pke and Wolfgang Gaissmaier},
  journal={Multiple sclerosis},
  year={2010},
  volume={16 12},
  pages={
          1507-12
        }
}
BACKGROUND Natalizumab is associated with the potentially life-threatening side-effect progressive multifocal leukoencephalopathy (PML). Little is known about patients' and physicians' risk estimates and attitudes towards natalizumab treatment. METHODS Consecutive natalizumab-treated patients (n = 69) and neurologists (n = 66) in two centres and cooperating private practices received an evidence-based three-page information leaflet about natalizumab-associated PML and an evaluation sheet… CONTINUE READING
Highly Cited
This paper has 31 citations. REVIEW CITATIONS
Tweets
This paper has been referenced on Twitter 11 times. VIEW TWEETS

From This Paper

Figures, tables, and topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 18 citations